CRELD1 and diabetes mellitus: This technology has led to the discovery of novel biomarkers such as Growth differentiation factor-15/Macrophage inhibitory cytokine-1 (GDF15/MIC-1), interleukin (IL)-18Ra, and Cysteine rich with EGF like domains 1 (CRELD1), which are indicative of disease progression in diabetes [13].